Literature DB >> 15930230

Is it safer to intubate premature infants in the delivery room?

Hany Aly1, An N Massaro, Kantilal Patel, Ayman A E El-Mohandes.   

Abstract

OBJECTIVES: Early nasal continuous positive airway pressure (ENCPAP) has recently emerged in neonatal units as an acceptable alternative to routine intubation and mandatory ventilation. The risks and benefits of ENCPAP have yet to be established. In this study, we aimed to examine variables that influenced the decision to initiate ENCPAP in the delivery room (DR). We also explored potential harmful effects of early intubation and examined whether unsuccessful ENCPAP attempts might subject infants to any unforeseen morbidity.
METHODS: All inborn very low birth weight (VLBW) infants admitted to the NICU since the implementation of the ENCPAP policy were included in this retrospective study. Infants were stratified initially into 2 cohorts according to whether they were intubated in the DR or began ENCPAP. Infants were then stratified into 4 groups according to the respiratory management during their first week of life. Infants in group 1 were supported with ENCPAP in the DR and continued to receive continuous positive airway pressure (CPAP) at least for the entire first week. Infants in group 2 began ENCPAP treatment in the DR but required intubation during the first week of life. Infants in group 3 were intubated in the DR but transitioned successfully to CPAP within the first 48 hours and were treated with CPAP for the first week of life or longer. Infants in group 4 were intubated in the DR and treated with intermittent mandatory ventilation for >48 hours. Univariate analyses compared different groups with the Wilcoxon nonparametric test, Kruskal-Wallis test, and analysis of variance. A multivariate regression model adjusted for differences in birth weights (BWs), gestational ages (GAs), race, and Apgar scores between the groups.
RESULTS: A total of 234 VLBW infants (weight of <1500 g) were admitted to the NICU during the period from August 1997 to December 2003. The mean BW was 977.1 +/- 305.8 g, and the mean GA was 27.7 +/- 2.7 weeks. The overall mortality rate was 11.1%, and the incidence of bronchopulmonary dysplasia among survivors was 17.4%. ENCPAP was implemented successfully in the DR for 151 (64.5%) infants, whereas 83 (35.5%) infants required intubation. Infants who required intubation had significantly lower GAs, BWs, and 1-minute Apgar scores. The use of ENCPAP in the DR increased significantly over time. The chance of successful maintenance with ENCPAP for >48 hours was not demonstrable at <24 weeks of gestation (10% success). Use of ENCPAP improved significantly by 25 weeks of gestation (45% success). Infants in group 1 required a shorter duration of oxygen use than did infants in group 3 (7.9 +/- 18.3 vs 39 +/- 32.7 days; regression coefficient [b] = 19 +/- 5.3). None of the infants in group 1 developed intraventricular hemorrhage of grade III or IV or retinopathy of prematurity of stage 3 or 4. Infants in group 3 did not show improved outcomes, compared with group 1. Compared with group 4, infants in group 2 had a higher incidence of necrotizing enterocolitis (15.6% vs 7.3%; b = 2.5 +/- 1.2).
CONCLUSIONS: The success of ENCPAP improved with increased GA and with staff experience over time. Infants treated successfully with ENCPAP were unlikely to develop intraventricular hemorrhage of grade III or IV. Infants who experienced ENCPAP failure were at increased risk for the development of necrotizing enterocolitis. Infants who were intubated briefly in the DR were at increased risk for prolonged oxygen requirement. An individualized approach should be considered for respiratory support of VLBW infants.

Entities:  

Mesh:

Year:  2005        PMID: 15930230     DOI: 10.1542/peds.2004-2493

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  22 in total

Review 1.  CPAP review.

Authors:  Olie Chowdhury; Catherine J Wedderburn; Donovan Duffy; Anne Greenough
Journal:  Eur J Pediatr       Date:  2011-12-16       Impact factor: 3.183

2.  Tidal volume delivery during surfactant administration in the delivery room.

Authors:  Georg M Schmölzer; C Omar F Kamlin; Jennifer A Dawson; Colin J Morley; Peter G Davis
Journal:  Intensive Care Med       Date:  2011-11       Impact factor: 17.440

3.  To intubate or not--that is the question: continuous positive airway pressure versus surfactant and extremely low birthweight infants.

Authors:  N Finer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-11       Impact factor: 5.747

Review 4.  Prevention and treatment of bronchopulmonary dysplasia: contemporary status and future outlook.

Authors:  Laura Cerny; John S Torday; Virender K Rehan
Journal:  Lung       Date:  2008-01-30       Impact factor: 2.584

5.  Surfactant utilization and short-term outcomes in an era of non-invasive respiratory support in Canadian neonatal intensive care units.

Authors:  K Raghuram; A Mukerji; J Young; W Yee; M Seshia; K Dow; V Shah
Journal:  J Perinatol       Date:  2017-06-29       Impact factor: 2.521

Review 6.  The Role of Caffeine in Noninvasive Respiratory Support.

Authors:  Nicole R Dobson; Ravi Mangal Patel
Journal:  Clin Perinatol       Date:  2016-09-28       Impact factor: 3.430

7.  Patent ductus arteriosus in premature infants: to treat or not to treat?

Authors:  M A Mohamed; M El-Dib; S Alqahtani; K Alyami; A N Ibrahim; H Aly
Journal:  J Perinatol       Date:  2017-02-16       Impact factor: 2.521

8.  Early nasal injury resulting from the use of nasal prongs in preterm infants with very low birth weight: a pilot study.

Authors:  Nathalie Tiemi Ota; Josy Davidson; Ruth Guinsburg
Journal:  Rev Bras Ter Intensiva       Date:  2013 Jul-Sep

Review 9.  Clinical practice : noninvasive respiratory support in newborns.

Authors:  J Peter de Winter; Machteld A G de Vries; Luc J I Zimmermann
Journal:  Eur J Pediatr       Date:  2010-02-24       Impact factor: 3.183

10.  Consequences of neonatal resuscitation with supplemental oxygen.

Authors:  Richard J Martin; G Bradley Bookatz; Steven L Gelfand; Juan Sastre; Alessandro Arduini; Marta Aguar; Raquel Escrig; Máximo Vento
Journal:  Semin Perinatol       Date:  2008-10       Impact factor: 3.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.